The Trump administration announced deals that will lower the prices of major obesity drugs for many Americans. Under the deals with Eli Lilly and Novo Nordisk, those buying injectable GLP-1 medications directly from the companies will pay an average of $350 per month, but the drugmakers have committed to reducing the price to around $250 over the next two years, according to senior administration officials. If oral GLP-1 tablets are approved by the US Food and Drug Administration, the lowest dose will cost $149.

See Full Page